128 signals · bluesky, newsapi, News / RSS
Scores are directional signals derived from aggregated public data — not verified findings or investment advice. Methodology
Signal-based estimates from public data — not verified assessments. Learn more
Moderate stress signals detected across available public data.
Low-to-moderate risk signals with no major red flags in current data.
Auto-generated from public signals — AI summary pending. Based on 3 recent signals.
Bernstein Lifts AstraZeneca PT, Affirms Outperform Rating marketscreener.com
RBC Raises Price Target on AstraZeneca to GBP152.50 From GBP145, Keeps Outperform Rating www.marketscreener.com
Biopharmaceutical company with oncology focus.
Based on 128 signals across 3 sources · snapshot 4 Nov 2026
Strong: enough recent evidence to trust this score.
Overall community sentiment for AstraZeneca is positive based on public signals as of 4 Nov 2026.
Based on 128 signals across 3 sources
Scores are directional signals derived from public data — not certified assessments or recommendations. Confidence indicates data coverage, not accuracy. Learn how scores are calculated →
Derived from public sources such as news, filings, and reported events.
AstraZeneca price target raised to 15,250 GBp from 14,500 GBp at RBC Capital TipRanks